Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int J Pharm ; 648: 123624, 2023 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-37984619

RESUMO

Androgenetic alopecia (AGA) is the primary hair loss with impairing patients' quality of life. Finasteride (FIN) is an SRD5A2 inhibitor for AGA treatment, but oral FIN causes systemic adverse effects. Topical FIN delivery is anticipated to overcome this problem. Ferulic acid (FA) is a natural phenolic acid with vascular remodeling and anti-inflammatory effects. Herein, an active pharmaceutical ingredient ionic liquid (API IL) based on choline and FA (CF-IL) is for the first time constructed to load FIN for fabricating FIN CF-IL. CF-IL aims to act as carriers and cargos and enhance hair follicle (HF) co-delivery of FA and FIN for synergistic anti-alopecia. Thermal and spectroscopic analysis combined with quantum chemistry calculations and molecular dynamics confirm the formation of CF-IL. The CF-IL simultaneously increases the solubility of FA (∼648-fold) and FIN (∼686-fold), enhances the permeation and retention of FIN and FA through the follicular pathway, and promotes cellular uptake. FIN CFIL regulates the abnormal mRNA expressions in dihydrotestosterone-irritated hDPCs, and promotes hair regrowth in AGA mice in a combined manner with FIN and FA. These findings suggest that FA-based API IL is a promising approach for percutaneously co-delivering FA and FIN to HF, providing an enhanced targeting treatment for AGA.


Assuntos
Finasterida , Líquidos Iônicos , Humanos , Camundongos , Animais , Finasterida/efeitos adversos , Preparações Farmacêuticas , Qualidade de Vida , Alopecia/tratamento farmacológico , Proteínas de Membrana , 3-Oxo-5-alfa-Esteroide 4-Desidrogenase
2.
Pharmaceutics ; 15(5)2023 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-37242742

RESUMO

Rheumatoid arthritis (RA) is an autoimmune disease of synovial inflammation that affects populations worldwide. Transdermal drug delivery systems for treating RA have increased but remain challenging. We fabricated a dissolving microneedle (MN) system with photothermal (PT) polydopamine (PDA) to co-load the non-steroidal anti-inflammatory drug loxoprofen (Lox) and the Janus kinase inhibitor tofacitinib (Tof), with the aim of co-delivering Lox and Tof directly to the articular cavity, aided by the combination of MN and PT. In vitro and in vivo permeation studies showed that the PT MN significantly promoted drug permeation and retention in the skin. An in vivo visualization of the drug distribution in the articular cavity showed that the PT MN significantly promoted drug retention in the articular cavity. Importantly, compared to the intra-articular injection of Lox and Tof, the application of the PT MN to a carrageenan/kaolin-induced arthritis rat model exhibited superior performance in reducing joint swelling, muscle atrophy, and cartilage destruction. Furthermore, the PT MN downregulated the mRNA expression levels of proinflammatory cytokines, including TNF-α, IL-1ß, iNOS, JAK2, JAK3, and STAT3. The results show that the PT MN transdermal co-delivery of Lox and Tof is a new synergetic therapy with high compliance and good therapeutic efficacy for RA.

3.
Int J Pharm ; 637: 122880, 2023 Apr 25.
Artigo em Inglês | MEDLINE | ID: mdl-36958612

RESUMO

Transdermal delivery of drugs is commonly limited by low skin permeability. The aim of the study was to synthesize deep eutectic solvents (DESs) based on oxymatrine (OMT) and fatty acids with various alkyl chain lengths (LCFAs) as novel vehicles, to solubilize the water-insoluble drug and enhance percutaneous penetration. Quercetin (QUE) was selected as a model drug. Combining differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), nuclear magnetic resonance (NMR), and molecular simulations demonstrated that the formation of DESs was mediated by charge-assisted hydrogen bonding. Physicochemical properties including stability, viscosity, and solubilization capacity were also studied. Subsequently, the effect of three stable DESs on drug release and skin permeability was evaluated. The results showed that QUE was solubilized well and presented a different sustained release behavior in DESs. Meanwhile, DESs enhanced the skin permeation of OMT and QUE, which was influenced by alkyl chain lengths of LCFAs, whereas DES consisting of lauric acid (LA) exhibited the highest enhancing effect. FTIR, DSC, and molecular docking further demonstrated consistency between micro molecular mechanism and macro penetration behavior. Additionally, HaCaT cells treated with DESs showed high cell viability, suggesting their good skin safety. Taken together, OMT-LCFA DESs would be a promising penetration enhancer for transdermal drug delivery, which also provides guidance for the design of new DESs.


Assuntos
Alcaloides , Solventes Eutéticos Profundos , Ácidos Graxos , Simulação de Acoplamento Molecular , Administração Cutânea , Preparações Farmacêuticas , Solventes/química
4.
Carbohydr Polym ; 277: 118819, 2022 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-34893236

RESUMO

Psoriasis does not respond adequately to the monotherapy, tailoring combined strategies for synergistical treatment remains challenging. We fabricated chitosan/hyaluronan nanogels to co-load methotrexate (MTX) and 5-aminoleavulinic acid (ALA), i.e., MTX-ALA NGs, for a combined chemo-photodynamic therapy for psoriasis. Compared with MTX-ALA suspension, the NGs enhanced the penetration and retention of MTX and ALA through and into the skin in vitro and in vivo (p < 0.001). NGs enhanced the cellular uptake (p < 0.001), protoporphyrin IX conversion (p < 0.001), and reactive oxygen species generation (3.93-fold), subsequently exerted the synergistical anti-proliferation and apoptosis on lipopolysaccharide-irritated HaCaT cells with the apoptosis rate of 78.6%. MTX-ALA NGs efficiently ameliorated the skin manifestations and down-regulated the proinflammatory cytokines of TNF-α and IL-17A in imiquimod-induced psoriatic mice (p < 0.001). Importantly, MTX-ALA NGs reduced the toxicities of oral MTX to the liver and kidney. The results support that MTX-ALA NG is a convenient, effective, and safe combined chemo-photodynamic strategy for psoriasis treatment.


Assuntos
Ácidos Levulínicos/uso terapêutico , Metotrexato/uso terapêutico , Nanogéis/química , Fármacos Fotossensibilizantes/uso terapêutico , Psoríase/tratamento farmacológico , Linhagem Celular , Quitosana/química , Quimioterapia Combinada , Humanos , Ácido Hialurônico/química , Ácidos Levulínicos/química , Lipopolissacarídeos , Metotrexato/química , Fármacos Fotossensibilizantes/química , Psoríase/induzido quimicamente , Psoríase/metabolismo , Ácido Aminolevulínico
5.
J Immunol ; 198(10): 4086-4095, 2017 05 15.
Artigo em Inglês | MEDLINE | ID: mdl-28411188

RESUMO

Raf kinase inhibitor protein (RKIP) protects against host immunological responses in nematodes and Drosophila Whether RKIP functions in innate immune responses in mammals remains unknown. In this article, we report that RKIP preferentially regulates the TLR3-mediated immune response in macrophages. RKIP deficiency or silencing significantly decreases polyinosinic:polycytidylic acid [Poly(I:C)]-induced IFN-ß, IL-6, and TNF-α production without affecting the counterpart induced by LPS or CpG. Compared with their wild-type counterparts, RKIP-deficient mice produce less IFN-ß, IL-6, and TNF-α in serum and display decreased lethality upon peritoneal Poly(I:C) plus d-galactosamine injection. Mechanistically, RKIP interacts with TBK1 and promotes the Poly(I:C)-induced TANK-binding kinase 1/IRF3 activation. Simultaneously, RKIP enhances the Poly(I:C)-induced interaction between TGF-ß-activated kinase 1 and MAPK kinase 3 (MKK3), thus promoting MKK3/6 and p38 activation. We further demonstrated that Poly(I:C) treatment, but not LPS treatment, induces RKIP phosphorylation at S109. This action is required for RKIP to promote TANK-binding kinase 1 activation, as well as the interaction between TGF-ß-activated kinase 1 and MKK3, which lead to activation of the downstream IRF3 and p38, respectively. Therefore, RKIP acts as a positive-feedback regulator of the TLR3-induced inflammatory response and may be a potential therapeutic target for inflammatory disease.


Assuntos
Inflamação/imunologia , Proteína de Ligação a Fosfatidiletanolamina/metabolismo , Transdução de Sinais , Receptor 3 Toll-Like/imunologia , Receptor 3 Toll-Like/metabolismo , Animais , Linhagem Celular , Regulação da Expressão Gênica , Imunidade Inata , Inflamação/metabolismo , Fator Regulador 3 de Interferon/imunologia , Fator Regulador 3 de Interferon/metabolismo , Interferon beta/sangue , Interferon beta/imunologia , Interleucina-6/sangue , Interleucina-6/imunologia , Macrófagos/imunologia , Camundongos , Quinases de Proteína Quinase Ativadas por Mitógeno/metabolismo , Proteína de Ligação a Fosfatidiletanolamina/deficiência , Proteína de Ligação a Fosfatidiletanolamina/genética , Fosforilação , Poli I-C/administração & dosagem , Fator de Necrose Tumoral alfa/sangue , Fator de Necrose Tumoral alfa/imunologia
6.
Gut ; 66(4): 597-610, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-26801887

RESUMO

OBJECTIVE: Raf kinase inhibitor protein (RKIP) appears to control cancer cell metastasis and its expression in colonic tissue is related to colonic cancer development. We sought to identify the roles of RKIP in maintaining homeostasis of GI tract. DESIGN: The expression of RKIP was determined by immunohistochemistry and western blot analysis. RKIP knockout and wild-type mice were administered dextran sulfate sodium (DSS) or 2,4,6-trinitrobenzenesulfonic acid (TNBS) to induce experimental colitis, and the mice were assessed based on colitis symptoms and biochemical approaches. The mechanism was analysed using immunoprecipitation and pull-down experiments. RESULTS: The RKIP expression is positively correlated with the severity of IBD. RKIP deficiency protects mice from DSS-induced or TNBS-induced colitis and accelerated recovery from colitis. RKIP deficiency inhibits DSS-induced infiltration of acute-phase immune cells and reduces production of proinflammatory cytokines and chemokines in colon. RKIP deficiency inhibits DSS-induced or TNBS-induced colonic epithelial barrier damage and intestinal epithelial cell (IEC) apoptosis. RKIP deficiency also inhibits tumour necrosis factor-alpha-induced IEC apoptosis and colitis. Mechanistically, RKIP enhances the induction of P53-upregulated modulator of apoptosis by interacting with TGF-ß-activated kinase 1 (TAK1) and promoting TAK1-mediated NF-κB activation. This is supported by the observation that TAK1 activation is positively correlated with the expression of RKIP in human clinical samples and the development of IBD. CONCLUSIONS: RKIP contributes to colitis development by promoting inflammation and mediating IEC apoptosis and might represent a therapeutic target of IBD.


Assuntos
Apoptose , Colite/genética , Doença de Crohn/metabolismo , Células Epiteliais/química , MAP Quinase Quinase Quinases/metabolismo , Proteína de Ligação a Fosfatidiletanolamina/genética , Proteína de Ligação a Fosfatidiletanolamina/metabolismo , Animais , Apoptose/efeitos dos fármacos , Apoptose/genética , Colite/induzido quimicamente , Colite/metabolismo , Colite/patologia , Colite Ulcerativa/metabolismo , Sulfato de Dextrana , Células Epiteliais/efeitos dos fármacos , Células HCT116 , Homeostase/genética , Humanos , Mucosa Intestinal/citologia , Camundongos , Camundongos Knockout , Proteína de Ligação a Fosfatidiletanolamina/análise , Fosforilação , Índice de Gravidade de Doença , Ácido Trinitrobenzenossulfônico , Fator de Necrose Tumoral alfa/farmacologia
7.
EMBO J ; 35(23): 2553-2565, 2016 12 01.
Artigo em Inglês | MEDLINE | ID: mdl-27753621

RESUMO

TANK-binding kinase 1 (TBK1) activation is a central event in type I interferon production in anti-virus innate immunity. However, the regulatory mechanism underlying TBK1 activation remains unclear. Here we report that Raf kinase inhibitory protein (RKIP) is essential for TBK1 activation and type I interferon production triggered by viral infection. Upon viral infection, RKIP is phosphorylated at serine 109 (S109) by TBK1. Phosphorylation of RKIP enhances its interaction with TBK1 and in turn promotes TBK1 autophosphorylation. Mutation of RKIP S109 to alanine abrogates the interaction between RKIP and TBK1, and the anti-viral function of RKIP RKIP deficiency inhibits intracellular double-stranded RNA- or DNA-induced type I interferon production. Consistently, RKIP deficiency renders the mice more susceptible to vesicular stomatitis virus (VSV) and herpes simplex virus (HSV) infections. This study reveals a previously unrecognized positive feedback loop between RKIP and TBK1 that is essential for type I interferon production in anti-viral innate immunity.


Assuntos
Retroalimentação Fisiológica , Imunidade Inata , Interferon Tipo I/biossíntese , Proteína de Ligação a Fosfatidiletanolamina/metabolismo , Proteínas Serina-Treonina Quinases/metabolismo , Simplexvirus/imunologia , Vesiculovirus/imunologia , Animais , Células Cultivadas , Modelos Animais de Doenças , Herpes Simples/imunologia , Herpes Simples/patologia , Herpes Simples/virologia , Macrófagos/imunologia , Camundongos , Infecções por Rhabdoviridae/imunologia , Infecções por Rhabdoviridae/patologia , Infecções por Rhabdoviridae/virologia
8.
Cell Signal ; 26(12): 2930-9, 2014 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-25239187

RESUMO

The production of type I interferon must be tightly regulated, and the aberrant production of this protein is harmful or even fatal to the host. The transcription factor IRF3 phosphorylation is a central regulator of type I interferon meditated antiviral response. Protein phosphatase-1 (PP1) has been reported to be important in many cell functions, including development, differentiation, and tumorigenesis. However, the roles of PP1 in Toll-like receptor (TLR)- or retinoic acid-inducible gene I like receptor (RLR)-triggered IRF-3 activation remain unclear. Here, we show that the activity of PP1 is downregulated in macrophages upon stimulation with TLR or RLR ligands, including lipopolysaccharide, and poly(I:C), or vesicular stomatitis virus (VSV), respectively. The overexpression of PP1 selectively inhibits TLR- and VSV-induced interferon regulatory factor 3 (IRF3) activation but has no substantial effect on TANK-binding kinase 1 (TBK1),ΚB kinase ε (IKKε) activation. Conversely, RNA interference of PP1 significantly promotes IRF3 activation. Consistently, The overexpression of PP1 inhibits TLR- and VSV-triggered IFN-ß production while PP1 knockdown significantly increases the production of IFN-ß in macrophages. We further demonstrate that PP1 directly interacts with IRF3 and dephosphorylates IRF3 at Ser385 and Ser396, resulting in the suppression of TLR- and RLR-triggered IFN-ß production. Thus, PP1 functions as a negative feedback regulator of TLR- and RLR-triggered antiviral immune responses by acting as an IRF3 phosphatase.


Assuntos
Fator Regulador 3 de Interferon/metabolismo , Interferon beta/metabolismo , Macrófagos/metabolismo , Fosfosserina/metabolismo , Proteína Fosfatase 1/metabolismo , Receptores de Superfície Celular/metabolismo , Receptores Toll-Like/metabolismo , Animais , Regulação para Baixo , Genes Reporter , Células HEK293 , Humanos , Ligantes , Macrófagos/enzimologia , Camundongos , Fosforilação , Ligação Proteica , Serina/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...